In their study, the researchers investigated how PAF causes contractions in the esophageal smooth muscle of rats-a process that contributes to symptoms like chest tightness and difficulty ...

In their study, the researchers investigated how PAF causes contractions in the esophageal smooth muscle of rats—a process that contributes to symptoms like chest tightness and difficulty ...

Eli Lilly's bimagrumab led to weight loss that was due almost entirely to fat reduction when combined with semaglutide, marketed by rival Novo Nordisk as Wegovy. BMO Capital Markets called the data ...

The true etiology of the peak in C.M.'s anti-D antibody titer to 1:32, with subsequent conversion to a negative antibody status before delivery, cannot be explained with certainty. On the basis of ...

Eli Lilly is beefing up muscle health R&D, partnering with Juvena Therapeutics in a deal that includes an upfront fee and more than $650 million in milestones.

Application note 720008780EN: Demonstrates the measurement of antibody titer and aggregate analysis in a single run following a direct-connect ProA-SEC method.

Transition from healthy to diseased state is a cell-type-specific process, influenced by neighboring cells and resulting in functionally meaningful differences between pulmonary artery adventitial ...

Non-human primate pharmacokinetics data suggests IBIO-600, a potentially best-in-class long-acting anti-myostatin antibody, could have a human half-life as long as 130 days Additional interim in ...

Scientists have discovered an antibody treatment that may help prevent both muscle loss and bone density loss in people using GLP-1 drugs such as Ozempic and Wegovy after losing weight.

Research shows bimagrumab may prevent muscle and bone loss associated with weight loss medications like Wegovy, offering hope for safer treatment options.

San Diego-based iBio has signed a backloaded agreement with its existing partner AstralBio for a preclinical anti-myostatin antibody that it hopes can induce weight loss while retaining muscle ...